Fig. 5From: Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trialsTreatment preference to continue Ig20Gly treatment in the European study. Ig20Gly, immune globulin subcutaneous (human) 20%; IV, intravenous; SC, subcutaneousBack to article page